期刊文献+

Pyunkang-hwan (Pyunkang-Tang) ameliorates air pollutant-induced inflammatory hypersecretion of airway mucus and bleomycin-induced pulmonary fibrosis in rats

Pyunkang-hwan (Pyunkang-Tang) ameliorates air pollutant-induced inflammatory hypersecretion of airway mucus and bleomycin-induced pulmonary fibrosis in rats
原文传递
导出
摘要 OBJECTIVE: To investigate the effect of Pyunkanghwan(Pyunkang-tang) extract(PGT) on secretion of airway mucin in an experimental animal model involving hyperplasia of goblet cells and mucus hypersecretion, and to test its effects on bleomycin(BLM)-induced pulmonary fibrosis in vivo.METHODS: The protective activity of orally administered PGT was assessed in two rat pulmonary disease models. Effects on hypersecretion of pulmonary mucin in sulfur dioxide(SO_2)-induced bronchitis in rats were assessed by quantifying the amount of mucus secreted and examining histopathology in the tracheal epithelium. In a rat model for BLMinduced pulmonary fibrosis, toxicity to the pulmonary system was examined by measuring levels of malondialdehyde and hydroxyproline,indicators of lipid peroxides and collagen,respectively, in lung tissue 28 days post-BLM treatment. Serial sections of lung tissue were stained with Masson trichrome to visualize collagen deposition. Effects of PGT on collagen synthesis were also assessed in vitro, in a cell culture model.RESULTS: PGT inhibited mucin secretion and normalized SO_2-induced increased muco- substances in goblet cells. In the BLM- induced model,PGT decreased the characteristic histopathological features of lung fibrosis and inhibited fibrotic lesions, as indicated by decreased hydroxyproline content. PGT also inhibited the BLM-induced increase in malondialdehyde levels, demonstrating its protective effect against lipid peroxidation in cell membranes of the lung. In MLg 2908 mouse lung fibroblast cells, PGT decreased transforming growth factor(TGF)-β-stimulated type I collagen synthesis.CONCLUSION: PGT can inhibit both hypersecretion of airway mucins and pulmonary fibrosis. OBJECTIVE: To investigate the effect of Pyunkanghwan(Pyunkang-tang) extract(PGT) on secretion of airway mucin in an experimental animal model involving hyperplasia of goblet cells and mucus hypersecretion, and to test its effects on bleomycin(BLM)-induced pulmonary fibrosis in vivo.METHODS: The protective activity of orally administered PGT was assessed in two rat pulmonary disease models. Effects on hypersecretion of pulmonary mucin in sulfur dioxide(SO_2)-induced bronchitis in rats were assessed by quantifying the amount of mucus secreted and examining histopathology in the tracheal epithelium. In a rat model for BLMinduced pulmonary fibrosis, toxicity to the pulmonary system was examined by measuring levels of malondialdehyde and hydroxyproline,indicators of lipid peroxides and collagen,respectively, in lung tissue 28 days post-BLM treatment. Serial sections of lung tissue were stained with Masson trichrome to visualize collagen deposition. Effects of PGT on collagen synthesis were also assessed in vitro, in a cell culture model.RESULTS: PGT inhibited mucin secretion and normalized SO_2-induced increased muco- substances in goblet cells. In the BLM- induced model,PGT decreased the characteristic histopathological features of lung fibrosis and inhibited fibrotic lesions, as indicated by decreased hydroxyproline content. PGT also inhibited the BLM-induced increase in malondialdehyde levels, demonstrating its protective effect against lipid peroxidation in cell membranes of the lung. In MLg 2908 mouse lung fibroblast cells, PGT decreased transforming growth factor(TGF)-β-stimulated type I collagen synthesis.CONCLUSION: PGT can inhibit both hypersecretion of airway mucins and pulmonary fibrosis.
出处 《Journal of Traditional Chinese Medicine》 SCIE CAS CSCD 2016年第5期663-670,共8页 中医杂志(英文版)
关键词 Pyunkang-hwan(Pyunkang-tang) Air pollutants BLEOMYCIN Pulmonary fibrosis Airway mucin Pyunkang-hwan(Pyunkang-tang) Air pollutants Bleomycin Pulmonary fibrosis Airway mucin
  • 相关文献

参考文献21

  • 1Evans CM, Koo JS. Airway mucus: the good, the bad, the sticky. Pharmacol Ther 2009; 121(3): 332-348.
  • 2Hunninghake GW, Kalica AR. Approaches to the treatment of pulmonary fibrosis. Am J Respir Crit Care Med 1995; 151(3 Pt 1): 915-918.
  • 3Mapel DW, Samet JM, Coultas DB. Corticosteroid and treatment of idiopathic pulmonary fibrosis. Past, present and future. Chest 1996; 110(4): 1058-1067.
  • 4Lasky JA, Ortiz LA. Antifibrotic therapy for the treatment of pulmonary fibrosis. Am J Med Sci 2001; 322 (4): 213-221.
  • 5Mason RJ, Schwarz MI, Hunninghake GW,, Musson RA. NHLBI workshop summary pharmacological therapy for idiopathic pulmonary fibrosis. Past, present and future. Am J Respir Crit Care Med 1999; 160(5 Pt 1): 1771- 1777.
  • 6Hay J, Shahzeidi S, Laurent G. Mechanisms of bleomycin-induced lung damage. Arch Toxicol 1991; 65 (2): 81-94.
  • 7Zia S, Hyde DM, Giri SN. Development of a bleomycin hamster model of subchronic lung fibrosis. Pathology 1992; 24(3): 155-163.
  • 8Lazenby AJ, Crouch EC, McDonald JA, Kuhn C, 3rd ed. Remodeling of the lung in bleomycin-induced pulmonary fibrosis in the rat. An immunohistochemical study of laminin, type IV collagen, and fibronectin. Am Rev Respir Dis 1990; 142(1): 206-214.
  • 9Thrall RS, Swendsen CL, Shannon TH, et al. Correlation of changes in pulmonary surfactant phospholipids with compliance in bleomycin-induced pulmonary fibrosis in the rat. Am Rev Respir Dis 1987; 136(1): 113-118.
  • 10Crouch E. Pathology of pulmonary fibrosis. Am J Physiol 1990; 259(4 Pt 1): L159-L184.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部